Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Moderate Buy” by Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $45.8462.

JANX has been the subject of a number of research reports. Evercore set a $22.00 target price on shares of Janux Therapeutics in a research report on Monday, May 11th. Cantor Fitzgerald dropped their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. UBS Group downgraded shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $57.00 to $15.00 in a report on Wednesday, April 15th. Wedbush reduced their price objective on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Finally, Piper Sandler lowered their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, May 8th.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the sale, the vice president directly owned 32,270 shares in the company, valued at $457,265.90. This trade represents a 5.94% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Aberdeen Group plc increased its position in shares of Janux Therapeutics by 21.1% during the third quarter. Aberdeen Group plc now owns 345,476 shares of the company’s stock valued at $8,443,000 after buying an additional 60,188 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at about $536,000. Readystate Asset Management LP increased its position in shares of Janux Therapeutics by 38.0% during the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock valued at $23,472,000 after buying an additional 264,423 shares during the period. SG Americas Securities LLC increased its position in shares of Janux Therapeutics by 175.1% during the fourth quarter. SG Americas Securities LLC now owns 79,817 shares of the company’s stock valued at $1,101,000 after buying an additional 50,802 shares during the period. Finally, Rhenman & Partners Asset Management AB increased its position in shares of Janux Therapeutics by 125.1% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 225,377 shares of the company’s stock valued at $3,110,000 after buying an additional 125,250 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $13.56 on Friday. The company’s 50-day moving average is $14.49 and its 200 day moving average is $15.03. The company has a market capitalization of $826.89 million, a P/E ratio of -7.37 and a beta of 2.53. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. As a group, research analysts predict that Janux Therapeutics will post -1.7 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.